India's Zydus Cadila could be about to shake up the India market for diabetes drugs with its Nov. 20 launch of Tenglyn (teneligliptin) for controlling hypoglycemia associated with the Type 2 version of the disease.
Germany's Merck KGaA has for some years been taking steps to cash in on the growing population in emerging markets of people needing treatment for diabetes and associated conditions, sometimes building plants to make its diabetes treatments locally. Working through a joint venture, a plant is starting production in North Africa.
Sanofi, stockpiling diabetes assets with eyes on Novo Nordisk and Eli Lilly, inked a deal worth up to $1.7 billion to bring in a late-stage treatment for the disease, partnering up with Lexicon Pharmaceuticals.
U.S. payers have put the screws to diabetes drug prices. New launches have churned up stable drug classes. New outcomes data seem certain to shake things up, too. But diabetes-focused Novo Nordisk just keeps sailing along.
Last year, AstraZeneca predicted its forthcoming diabetes combo med could generate peak annual sales of $3 billion. But those revenues will have to wait. The FDA has turned down the drug, which combines AZ's DPP-4 therapy, Onglyza, with SGLT2 contender Farxiga.
The FDA wants to see more clinical trial data on AstraZeneca's new combination diabetes treatment, the company said, likely delaying a potential launch by more than a year.
Since Eli Lilly and Boehringer Ingelheim announced that their SGLT2 med, Jardiance, had become the first to show it could lower the risk of major cardiovascular events, the question on the minds of industry watchers has been "How much?"
Zealand Pharma has taken a step toward collecting milestones worth up to $160 million (€142 million) and double-digit royalties. The paydays are tied to the success of its diabetes alliance with Sanofi, the prospects of which were buoyed this week with the release of Phase III data.
Novo Nordisk is out trumpeting new data on its next-gen basal insulin Tresiba and a combo med, Xultophy. New studies to brag about are always good things. But they're particularly well-timed now, with the FDA on the verge of a decision on Tresiba--and analysts fairly certain that the drug will get the agency's stamp of approval.
LONDON-- Late last month, partners Eli Lilly and Boehringer Ingelheim announced that their SGLT2 diabetes med, Jardiance, had gone where no others had gone before. While its rivals had always either increased the risk of cardiovascular events or, at best, had no effect, the newcomer showed it could actually lower the risk of heart attack, stroke and death from cardiovascular causes.